RT Journal
A1 Sacco KA, Termine A, Seyal A, et al
T1 Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms
JF Archives of General Psychiatry
JO Archives of General Psychiatry
YR 2005
FD June 1
VO 62
IS 6
SP 649
OP 659
DO 10.1001/archpsyc.62.6.649
UL http://dx.doi.org/10.1001/archpsyc.62.6.649
AB Background 
    Cigarette smoking rates in schizophrenia are higher than in the general population.Objectives 
    To determine whether cigarette smoking modifies cognitive deficits in schizophrenia and to establish the role of nicotinic acetylcholine receptors (nAChRs) in mediating cigarette smoking–related cognitive enhancement.Design 
    Neuropsychological assessments were performed at smoking baseline, after overnight abstinence, and after smoking reinstatement across 3 separate test weeks during which subjects were pretreated in a counterbalanced manner with the nonselective nAChR antagonist mecamylamine hydrochloride (0, 5, or 10 mg/d).Participants 
    Twenty-five smokers with schizophrenia and 25 control smokers.Setting 
    Outpatient mental health center.Main Outcome Measures 
    Visuospatial working memory (VSWM) and Continuous Performance Test (CPT) scores.Results 
    In smokers with schizophrenia and control smokers, overnight abstinence led to undetectable plasma nicotine levels and an increase in tobacco craving. While abstinence reduced CPT hit rate in both groups, VSWM was only impaired in smokers with schizophrenia. Smoking reinstatement reversed abstinence-induced cognitive impairment. Enhancement of VSWM and CPT performance by smoking reinstatement in smokers with schizophrenia, but not the subjective effects of smoking, was blocked by mecamylamine treatment.Conclusions 
    Cigarette smoking may selectively enhance VSWM and attentional deficits in smokers with schizophrenia, which may depend on nAChR stimulation. These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.